US Oncology Research, The US Oncology Network and McKesson Specialty Health Affiliated Investigators
US Oncology Research, The US Oncology Network and McKesson Specialty Health Affiliated Investigators Participate in 90 Studies Featured at ASCO 2013
Studies have a wide-range of focus including trials with novel chemotherapy regimens, radiation therapy, vaccine therapy, trials with small molecules targeting sub-sets of cancer, and novel combinations of therapies
THE WOODLANDS, Texas--(BUSINESS WIRE)-- More than 85 leading investigators affiliated with US Oncology Research, The US Oncology Network and McKesson Specialty Health participated in 90 studies that will be presented, displayed or published at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 31-June 4 at McCormick Place in Chicago. Of those studies, 11 will be presented as oral presentations, three as educational/special sessions and 45 as poster presentations.
Daniel Von Hoff, M.D., F.A.C.P., chief scientific officer for US Oncology Research and physician in chief and director of translational research at the Translational Genomics Research Institute (TGen), is presenting a study titled, "Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates." During the oral presentation, Dr. Von Hoff will detail the results of the study and explain why the outcomes could have a significant impact on how patients with pancreatic cancer are treated.
"Studies such as this one allow us to make significant strides in our fight against advanced pancreatic cancer, a disease that is very difficult to treat because early detection is so difficult," said Dr. Von Hoff. "More than 850 patients with metastatic pancreatic cancer treated at over 150 community and academic centers participated in this important trial (based on solid basic science), which is a new standard in the treatment of patients with pancreatic cancer and could become a backbone for new regimens."
Dr. Von Hoff was also involved in a study titled, "Integrating molecular profiling into cancer treatment decision making: Experience with over 35,000 cases," as another oral presentation at the ASCO annual meeting. This trial is evidence of the growing shift in clinical cancer research, where more investigators are focusing on biomarkers and molecular diagnostics to better understand the biology of a patient's tumor. The study also provides important leads for clinical trials with both established and investigational new agents.
"Our affiliated investigators were involved in 90 studies featured at ASCO this year, and many of those studies involve a biomarker or targeted molecule," said Lisa Holland, vice president of US Oncology Research, which is supported by McKesson Specialty Health. "We are honored to participate in designing and conducting clinical trials that focus on the science, looking for the most effective opportunities that will benefit a patient's care. For example, we had the opportunity to lead enrollment in the U.S. for several studies with novel combination therapies as well as studies that have been practice-changing for patients affected by cancer. Due to the size and connectivity of our network, we are fortunate to be able to identify patients for the smaller, targeted trials, as well as continue to accrue on larger trials across the network. We are committed to supporting our affiliated investigators with clinical trial opportunities for patients and are very proud of their strong presence at this year's ASCO meeting."
A part of McKesson Specialty Health, US Oncology Research enables community-based oncologists, many of whom are affiliated with The US Oncology Network, to participate in clinical research studies. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, the physicians affiliated with US Oncology Research have played a role in the development of 46 FDA-approved cancer fighting therapies.
ASCO presentations that affiliated investigators are part of:
Editor Note: Please contact Claire Crye (281) 863-6783 / (281) 825-9927 or via email at Claire.Crye@mckesson.com to set up an interview with any investigator in bold.
Oral Presentations:
1. | Saturday, June 1, 1:30pm - 1:45pm, E354a | ||||
Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study | |||||
John Leonard, Nina D. Wagner-Johnston, Steven E. Coutre, Ian Flinn, Marshall T. Schreeder, Nathan Hale Fowler, Jeff Porter Sharman, Ralph V. Boccia, Jacqueline Claudia Barrientos, Kanti Roop Rai, Thomas E. Boyd, Richard R. Furman, Leanne Holes, David Michael Johnson, Yeonhee Kim, Roger D. Dansey, Wayne R. Godfrey, Sven De Vos | |||||
2. | Saturday, June 1, 1:30pm-1:45pm, E354a | ||||
Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL) | |||||
Nina D. Wagner-Johnston, Sven De Vos, John Leonard, Jeff Porter Sharman, Marshall T. Schreeder, Ralph V. Boccia, Jacqueline Claudia Barrientos, Steven E. Coutre, Ian Flinn, Thomas E. Boyd, Leanne Holes, David Michael Johnson, Yeonhee Kim, Roger D. Dansey, Wayne R. Godfrey, Nathan Hale Fowler | |||||
3. | Saturday, June 1, 3:45pm - 4:00pm, S406 | ||||
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma | |||||
Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Susan Doleman, Yining Ye, Ari M. Vanderwalde, Robert Coffin, Howard Kaufman | |||||
4. | Sunday, June 2, 8:15am-8:30am, E354b | ||||
Integrating molecular profiling into cancer treatment decision making: Experience with over 35,000 cases | |||||
Zoran Gatalica, Sherri Millis, Sting Chen, Gargi Dan Basu, Wenhsiang Wen, Les Paul, Ryan P. Bender, Daniel D. Von Hoff | |||||
5. | Sunday, June 2, 9:15am - 9:30am, N Hall B1 | ||||
Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3) | |||||
Ruth O'Regan, Mustafa Ozguroglu, Fabrice Andre, Masakazu Toi, Guy Heinrich Maria Jerusalem, Sharon Wilks, Claudine Isaacs, Binghe Xu, Norikazu Masuda, Francis P. Arena, Denise Aysel Yardley, Yoon Sim Yap, Pabak Mukhopadhyay, Shyanne Douma, Mona El-Hashimy, Tanya Taran, Tarek Sahmoud, David Edward Lebwohl, Luca Gianni | |||||
6. | Monday, June 3, 11:15am-11:30am, E Hall D1 | ||||
Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates | |||||
Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Malcolm J. Moore, Thomas E. Seay, Sergei Tjulandin, Wen Wee Ma, Mansoor N. Saleh, Marion Harris, Michele Reni, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, Eric Van Cutsem, David Goldstein, Xinyu Wei, Jose Luis Iglesias, Markus Frederic Renschler | |||||
7. | Monday, June 3, 4:00pm - 4:15pm, E Hall D2 | ||||
Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) | |||||
Ralph Zinner, Helen J. Ross, Robert Weaver, Ramaswamy Govindan, Viran R. Holden, Naveed Mahfooz Chowhan, J. Thaddeus Beck, David Michael Waterhouse, Manuel Modiano, Vijay Phooshkooru Rao, Jingyi Liu, Andrew Koustenis, Symantha Melemed, Susan C. Guba, Waldo Feliu Ortuzar, Durisala Desaiah, David R. Spigel, Coleman K. Obasaju | |||||
8. | Monday, June 3, 4:15pm - 4:30pm, E Hall D2 | ||||
A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results | |||||
Mark A. Socinski, Jyoti D. Patel, Edward B. Garon, Ramaswamy Govindan, Craig H. Reynolds, David R. Spigel, Mark R. Olsen, Jingyi Liu, Susan C. Guba, Philip Bonomi | |||||
9. | Monday, June 3, 5:30pm - 5:45pm, E Hall D2 | ||||
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) | |||||
David R. Spigel, Scott N. Gettinger, Leora Horn, Roy S. Herbst, Leena Gandhi, Michael S. Gordon, Cristina Cruz, Paul Conkling, Philippe Alexandre Cassier, Scott J. Antonia, Howard A. Burris, Gregg Daniel Fine, Ahmad Mokatrin, Marcin Kowanetz, Xiaodong Shen, Daniel S. Chen, Jean-Charles Soria | |||||
10. | Tuesday, June 4, 9:45am - 10:00am, E Hall D1 | ||||
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. | |||||
Charles Andrew Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Jerzy Krzakowski, Sergiusz Nawrocki, Tudor-Eliade Ciuleanu, Lionel Bosquée, Jose Manuel Trigo Perez, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Christoph Helwig, Martin H. Falk, Frances A. Shepherd | |||||
11. | Tuesday, June 4, 10:15am - 10:30am, E Hall D1 | ||||
A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617 | |||||
Jeffrey D Bradley, Rebecca Paulus, Ritsuko Komaki, Gregory A. Masters, Kenneth Forster, Steven E. Schild, Jeffrey Bogart, Yolanda I. Garces, Samir Narayan, Vivek Kavadi, Lucien Alexander Nedzi, Jeff M. Michalski, Douglas Johnson, Robert Malcolm MacRae, Walter John Curran, Hak Choy | |||||
Educational and Special Sessions:
1. | Friday, May 31, 3:45 pm - 6:00 pm | ||||
Career Choices: Options in Academia, Practice, Industry, and Government | |||||
Dr. Fadi Braiteh | |||||
2. | Saturday, June 1, 4:45 pm - 6:00 pm | ||||
Is Age Just a Number? Adjuvant Therapy Decision Making for Older and/or Frail Patients with Cancer | |||||
Dr. Cynthia Osborne | |||||
3. | Monday, June 3, 1:15 pm - 2:30 pm | ||||
Women in Oncology: Challenges and Keys to Success | |||||
Dr. Debra Patt | |||||
Poster Presentations :
1. | Saturday, June 1, 1:15pm - 5:00pm, S Hall A2 | ||||
Eribulin mesylate (Erib) plus capecitabine (X) for adjuvant treatment in post-menopausal estrogen receptor-positive (ER+) early-stage breast cancer: Phase II, multicenter, single-arm study | |||||
John W. Smith, Jessicca Rege, Hina Maniar, James Song, David Cox, Joyce O'Shaughnessy | |||||
2. | Saturday, June 1, 1:15pm - 5:00pm, S Hall A2 | ||||
ER as a predictor of early breast cancer (EBC) outcomes in patients | |||||
O'Shaughnessy J, Loesch D, Paul D, Stokoe T, Pippen JE, Blum JL, Krekow LK, Holmes FA, Vukelja SJ, Lindquist DL, Sandbach JF, Sedlacek SM, Wang Y, Jones S | |||||
3. | Saturday, June 1, 1:15pm - 5:00pm, S Hall A2 | ||||
Identification of the activated form of the progesterone receptor (PR) in breast cancer (BC) | |||||
Jacques Bosq, Jean-Michel Caillaud, Carol A. Lange, Suzanne A. W. Fuqua, Joyce O'Shaughnessy, Erard M. Gilles, Alexander A. Zukiwski, Jacques Bonneterre | |||||
4. | Saturday, June 1, 1:15pm - 5:00pm, S Hall A2 | ||||
Independent characterization by duel staining of progesterone receptor (PR) and estrogen receptor (ER) in breast cancer (BC) | |||||
Alexander A. Zukiwski, Jean-Michel Caillaud, Jacques Bosq, Suzanne A. W. Fuqua, Carol A. Lange, Joyce O'Shaughnessy, Erard M. Gilles, Jacques Bonneterre | |||||
5. | Saturday, June 1, 1:15pm - 5:00pm, S Hall A2 | ||||
Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC) | |||||
Ute Hoch, Dennis G. Fry, Yen Lin Chia, Katie Caygill, Alison L. Hannah, Edith A. Perez, Javier Cortez, Ahmad Awada, Joyce O'Shaughnessy, Christopher Twelves, Hope S. Rugo, Seock-Ah Im, Binghe Xu, Kenna Lynn Anderes, Darren W. Davis | |||||
6. | Saturday, June 1, 3:00pm - 6:00pm, E253 | ||||
Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825 | |||||
Jeffrey Scott Wefel, Stephanie L. Pugh, Terri S. Armstrong, Mark R. Gilbert, Minhee Won, Merideth M. Wendland, David Brachman, Ritsuko Komaki, Ian R. Crocker, H. Ian Robins, R. Jeffrey Lee, Minesh P. Mehta | |||||
7. | Monday, June 3, 8:00am - 12:00pm, E450a | ||||
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation | |||||
Jeffrey J. Raizer, Pierre Giglio, Jethro Lisien Hu, Morris D. Groves, Ryan Merrell, Charles A. Conrad, Surasak Phuphanich, Vinay K. Puduvalli, Monica Elena Loghin, Nina Paleologos, W. K. Alfred Yung, Brian D. Vaillant, Jeremy David Rudnick, Marc C. Chamberlain, Nicholas Vick, Sean Aaron Grimm, Ivo Tremont-Lukats, John Frederick De Groot, Kenneth D. Aldape, Mark R. Gilbert | |||||
8. | Saturday, June 1, 8:00am - 11:45am, S Hall A2 | ||||
RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma | |||||
Prakash Chinnaiyan, Minhee Won, Patrick Y. Wen, Amyn Rojiani, Merideth M. Wendland, Thomas A. DiPetrillo, Benjamin W. Corn, Minesh P. Mehta | |||||
9. | Monday, June 3, 8:00am - 11:45am, S Hall A2 | ||||
Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC) | |||||
Ashwin Gollerkeri, Michael S. Gordon, John M. Burke, Ralph Hauke, Jiri Tomasek, Donald A. Richards, Christopher DiSimone, Scott S. Tykodi, Amit R. Mehta, Charles Chen, Rachelle Perea, Nicholas J. Vogelzang | |||||
10. | Sunday, June 2, 8:00am - 11:45am, S Hall A2 | ||||
SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) | |||||
Allen Lee Cohn, J. Randolph Hecht, Shaker Dakhil, Mansoor N. Saleh, Bilal Piperdi, Vivian Jean M. Cline-Burkhardt, Ying Tian, William Y. Go | |||||
11. | Sunday, June 2, 8:00am - 11:45am, S Hall A2 | ||||
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors | |||||
Josep Tabernero, John D. Powderly, Omid Hamid, Michael S. Gordon, George A. Fisher, Fadi S. Braiteh, Lawrence E. Garbo, Gregg Daniel Fine, Marcin Kowanetz, Bruce McCall, Xiaodong Shen, Daniel S. Chen, Holbrook Edwin Kohrt | |||||
12. | Sunday, June 2, 8:00am - 11:45am, S Hall A2 | ||||
A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC) | |||||
Shawn MacKenzie, Herbert Zeh, Laurence E. McCahill, Timothy D. Sielaff, Nathan Bahary, Thomas Edward Gribbin, John E. Seng, Joseph W. Leach, Jocelyn Harmon, Michael J. Demeure, Daniel D. Von Hoff, A Jim Moser, Ramesh K. Ramanathan | |||||
13. | Sunday, June 2, 8:00am - 11:45am, S Hall A2 | ||||
CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC) | |||||
E. Gabriela Chiorean, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, Jeffrey R. Infante, Venu Gopal Bathini, Tina Evans Wood, Paul N. Mainwaring, Robert T. Muldoon, Philip R. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Amy Ko, Brian Lu | |||||
14. | Sunday, June 2, 8:00am - 11:45am, S Hall A2 | ||||
Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC) | |||||
Malcolm J. Moore, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Jeremy K. Hon, Mikhail Yu Biakhov, Sunil R. Hingorani, Vinod Ganju, Colin D. Weekes, Werner Scheithauer, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Xinyu Wei, Alfredo Romano | |||||
15. | Sunday, June 2, 8:00am - 11:45am, S Hall A2 | ||||
A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers | |||||
Eunice Lee Kwak, Lipika Goyal, Thomas Adam Abrams, Amanda Carpenter, Brian M. Wolpin, Raymond Couric Wadlow, Jill N. Allen, Rebecca Suk Heist, Nadine Jackson McCleary, Jennifer A. Chan, Wolfram Goessling, Deborah Schrag, Colleen Evans, Kimmie Ng, Peter C. Enzinger, David P. Ryan | |||||
16. | Sunday, June 2, 8:00am - 11:45am, S Hall A2 | ||||
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM) | |||||
James R. Berenson, James D. Hilger, Robert Dichmann, Dipti Patel-Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, Hilda Chamras, Youram Nassir, Regina A. Swift, Robert A. Vescio | |||||
17. | Monday, June 3, 8:00am - 11:45am, S Hall A2 | ||||
A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial | |||||
John Sarantopoulos, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, Charles Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Jose Luis Iglesias, Guru Sonpavde, Theodore Logan, Noah M. Hahn, Christopher Sweeney, Thomas E. Hutson | |||||
18. | Monday, June 3, 8:00am - 11:45am, S Hall A2 | ||||
Rates of dose adjustment in patients treated with tivozanib versus sorafenib in the phase III TIVO-1 study | |||||
Thomas E. Hutson, Dmitry Nosov, Mihai Harza, Brooke Esteves, Andrew Louis Strahs, Anna Berkenblit, Robert John Motzer | |||||
19. | Monday, June 3, 8:00am - 11:45am, S Hall A2 | ||||
Impact of cytoreductive nephrectomy on disease-specific survival (DSS) in the cytokine and targeted therapy eras: Age- and TNM-stage matched analysis of SEER data | |||||
Rebecca A. Nelson, Nicholas J. Vogelzang, Sumanta Kumar Pal | |||||
20. | Saturday, June 1, 8:00am - 12:00pm, E450a | ||||
A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel | |||||
Kim N. Chi, Thian San Kheoh, Charles J. Ryan, Arturo Molina, Joaquim Bellmunt, Nicholas J. Vogelzang, Dana E. Rathkopf, Karim Fizazi, Philip W. Kantoff, Jinhui Li, Johann Sebastian De Bono, Howard I. Scher | |||||
21. | Saturday, June 1, 8:00am - 12:00pm, E450a | ||||
A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results | |||||
Emmanuel S. Antonarakis, Adam S Kibel, George Adams, Lawrence Ivan Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Robert Claude Tyler, Candice McCoy, Yang Wang, Nadeem A. Sheikh, Charles G. Drake | |||||
22. | Saturday, June 1, 8:00am - 12:00pm, E450a | ||||
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane | |||||
Daniel Peter Petrylak, Philip W. Kantoff, Anthony E. Mega, Nicholas J. Vogelzang, Joe Stephenson, Mark T. Fleming, Nancy Stambler, Michaela Petrini, Sara Blattman, Robert Joseph Israel | |||||
23. | Saturday, June 1, 8:00am - 12:00pm, E450a | ||||
An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort | |||||
Howard I. Scher, Matthew R. Smith, Christopher Sweeney, Paul Gettys Corn, Christopher Logothetis, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Daniel J. George, Johann Sebastian De Bono, Celestia S. Higano, Eric Jay Small, Jonathan Goldin, Matthew S. Brown, Dana T. Aftab, Mojtaba Noursalehi, Aaron Weitzman, Ethan M. Basch | |||||
24. | Monday, June 3, S Hall A2, 8:00am - 11:45am | ||||
Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts) | |||||
Celestia S. Higano, Andrew J. Armstrong, Matthew R. Cooperberg, Philip W. Kantoff, James Bailen, Raoul S. Concepcion, Vahan Kassabian, Shaker R. Dakhil, Steven E. Finkelstein, Jeffrey L. Vacirca, Robert M. Rifkin, Andrew Sandler, Candice McCoy, James Boyd Whitmore, Robert Claude Tyler, A. Oliver Sartor | |||||
25. | Monday, June 3, 8:00am - 11:45am, S Hall A2 | ||||
Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial | |||||
Chris Parker, Jose E. Garcia-Vargas, C. Gillies O'Bryan-Tear, Fang Fang, Nicholas J. Vogelzang | |||||
26. | Monday, June 3, 8:00am - 11:45am, S Hall A2 | ||||
Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer | |||||
Mark T. Fleming, Dana E. Rathkopf, Jackie Gibbons, Amy C. Peterson, Alison Hannah, David Forer, Howard I. Scher, Michael J. Morris | |||||
27. | Monday, June 3, 8:00am - 11:45am, S Hall A2 | ||||
Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial | |||||
Nicholas J. Vogelzang, Svein Inge Helle, Dag Clement Johannessen, Joe M. O'Sullivan, Jose E. Garcia-Vargas, C. Gillies O'Bryan-Tear, Minghua Shan, Chris Parker | |||||
